Alon Ben-Noon, CEO of NeuroSense Therapeutics
NeuroSense Therapeutics Announces Encouraging Interim Results of Clinical Study in ALS
The study, containing 15 patients, is scheduled to continue for an additional 6 months.
- Go to the previous page
- 1
- …
- 224
- 225
- 226
- 227
- 228
- 229
- 230
- …
- 245
- Go to the next page